Personalized Cancer Vaccine Extends Lives in Major Trial

A groundbreaking mRNA cancer vaccine tailored to each patient's tumor has successfully extended lives in a major melanoma trial.

The personalized treatment, combined with existing therapy, slashed cancer recurrence by 49% and could reach patients by early 2027.